Release date: 2017-04-17
Yesterday (April 13), Hengrui Pharmaceutical announced that the company intends to set up a subsidiary in Jiangsu. The company name is tentatively set to Suzhou Shengdi Pharmaceutical Co., Ltd. The company's business scope covers the research and development, production and sales of pharmaceutical products. The capital is 1.5 billion yuan.
Also on the same day, Suzhou Industrial Park official WeChat gave more information, the official micro shows that Hengrui Medical plans to establish Suzhou innovation and international base project in Suzhou Industrial Park, including the new drug preparation conversion base, the global clinical laboratory center and The Clinical Data Science Center, the Innovative Medicine and High-end Preparation Production Base, and Hengrui University, etc., established Suzhou Shengdi Pharmaceutical Co., Ltd. in the first phase, with a registered capital of 1.5 billion yuan.
Innovative drug conversion base
It carries the pilot test and production transformation of all the innovative drugs of Hengrui Medicine, with a construction area of ​​about 50,000 square meters.
Global Clinical Laboratory Center
As the global management headquarters of Hengrui Clinical Laboratory, responsible for and coordinating the clinical research and development of all innovative drugs of Hengrui Company; the Clinical Data Science Center will integrate global data resources, responsible for the collection, management, analysis, research, mining and storage of clinical data. Work to meet the needs of Hengrui's global new drug research and development, with a construction area of ​​about 50,000 square meters.
Innovative medicine and high-end preparation production base
Mainly responsible for the production of innovative drugs listed by Hengrui in the next 5 years and some high-end preparations exported to Europe and the United States. According to the time-to-market of new drugs, it is planned to be divided into two phases: the first phase of the project is planned to start in early 2018, and in 519, five innovative drugs and four high-end preparation workshops for export to Europe and the United States will be put into production; the second phase will be completed by 2022. It will start production of 6 innovative drugs, plus administrative facilities, quality inspection, public works and environmental protection systems, with a total construction area of ​​about 200,000 square meters.
Hengrui University
Hengrui University is responsible for the training, training and academic exchange of various types of talents in production, R&D and sales of the company, providing talent cultivation and intellectual support for the sustainable development of the company, with a construction area of ​​about 100,000 square meters.
As one of the leading companies in the domestic pharmaceutical industry, the actions of Hengrui Medicine have been receiving much attention. According to the 2016 annual report released by Hengrui Pharmaceutical, the company achieved revenue of 11.094 billion yuan last year, up 19.08% year-on-year; net profit attributable to shareholders of listed companies was 2.589 billion yuan, up 19.22% year-on-year. In addition, in 2016, the company invested a total of 1.18 billion yuan in research and development, an increase of 32.82% over the same period of the previous year.
Source: Medical Valley finishing
COVID-19 Antigen Test Cassette (Nasal Swab)
This detection kit applies immunoassay to directly detect the presence of virus and is possible to reach large-scale testing of up to millions of tests one day
COVID-19 Antigen Test Cassette (Nasal Swab)
NINGBO AUTRENDS INTERNATIONAL TRADE CO., LTD , https://www.metests.com